Amakem appoints new head of CMC and Operations

pharmafile | July 12, 2012 | Appointment | Business Services, Manufacturing and Production, Research and Development, Sales and Marketing  

Belgium-based Amakem NV has announced the appointment of Maarten van Geffen as head of CMC and Operations.

The kinase platform company which focuses on ophthalmology said van Geffen brings an exceptional track record in international management experience in pharmaceutical development to the company.

His career in the industry spans nearly 25 years, with substantial experience in pharma product development and regulatory affairs. He was previously director of Product Development at Shire-Movetis NV, where he was responsible for the development of the GI early- and late-phase products and was the CMC lead for due diligence of small and large molecule products.

Advertisement

While at the company, van Geffen also played a pivotal role in the strategic development of commercial and pipeline products as well as carrying out quality control on dossiers and interacting with regulatory authorities.

Prior to working at Shire-Movetis NV, van Geffen held several positions as director of CMC Regulatory Affairs at Barrier Therapeutic NV, Centocor BV, and Janssen Research Foundation, where he was involved in managing and executing product development and regulatory approval.

van Geffen said: “I am very excited to be joining Amakem and to have the opportunity to apply the experience I have gained as the company continues its development of AMA0076 for glaucoma and builds its pipeline.”

Related Content

No items found
The Gateway to Local Adoption Series

Latest content